Loading...
DXR logo

Daxor CorporationNasdaqCM:DXR Stock Report

Market Cap US$66.1m
Share Price
US$10.82
US$22.5
51.9% undervalued intrinsic discount
1Y35.3%
7D3.0%
1D
Portfolio Value
View

Daxor Corporation

NasdaqCM:DXR Stock Report

Market Cap: US$66.1m

DXR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Daxor Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Daxor
Historical stock prices
Current Share PriceUS$10.82
52 Week HighUS$14.76
52 Week LowUS$7.57
Beta0.29
1 Month Change9.85%
3 Month Change-11.38%
1 Year Change35.25%
3 Year Change11.78%
5 Year Change10.55%
Change since IPO101.30%

Recent News & Updates

Recent updates

Seeking Alpha Aug 25

Daxor reports Q2 results

Daxor press release (NASDAQ:DXR): Q2 The increase in revenue of 92.6 percent in the Company’s operating division represents strong strides in the commercialization of its BVA-100. As of June 30, 2022 the company held net assets of $19,615,712 or $4.85 per share, a 35.3 percent increase versus the same period in the prior year.
Seeking Alpha Jul 21

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor (NASDAQ:DXR) said it had partnered with Medaxiom to advance awareness and adoption of Daxor’s blood volume diagnostic. "With heart failure diagnosis continuing to increase, access to accurate blood volume testing will transform the way care decisions are made,” said Joe Sasson, MedAxiom’s EVP of Ventures.
Analysis Article Mar 08

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

We didn't see Daxor Corporation's ( NASDAQ:DXR ) stock surge when it reported robust earnings recently. We decided to...
Analysis Article Feb 27

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Daxor Corporation...

Shareholder Returns

DXRUS Medical EquipmentUS Market
7D3.0%3.0%-0.8%
1Y35.3%-18.3%27.1%

Return vs Industry: DXR exceeded the US Medical Equipment industry which returned -18.6% over the past year.

Return vs Market: DXR exceeded the US Market which returned 26.7% over the past year.

Price Volatility

Is DXR's price volatile compared to industry and market?
DXR volatility
DXR Average Weekly Movement7.0%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: DXR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DXR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1971n/aMichael Feldschuhwww.daxor.com

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.

Daxor Corporation Fundamentals Summary

How do Daxor's earnings and revenue compare to its market cap?
DXR fundamental statistics
Market capUS$66.14m
Earnings (TTM)US$9.17m
Revenue (TTM)US$26.69k
6.9x
P/E Ratio
2,363x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DXR income statement (TTM)
RevenueUS$26.69k
Cost of RevenueUS$0
Gross ProfitUS$26.69k
Other Expenses-US$9.14m
EarningsUS$9.17m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)1.57
Gross Margin100.00%
Net Profit Margin34,359.17%
Debt/Equity Ratio0%

How did DXR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 08:10
End of Day Share Price 2026/05/21 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daxor Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frank TakkinenLake Street Capital Markets, LLC
Scott HenryRoth Capital Partners